Javascript must be enabled to continue!
Linezolid-containing Treatment Regimens for Tuberculosis in Children
View through CrossRef
Background:
In recent years, there is an increasing interest in the use of linezolid for the treatment of tuberculosis (TB).
Methods:
Patients less than 18 years of age who received linezolid within the Spanish Pediatric TB Network from 2001 to 2016 were retrospectively included. Treatment characteristics, adverse events (AEs) and outcomes were analyzed.
Results:
Fifteen children were included (53% male) with a median age of 3.6 years [interquartile range (IQR): 1.6–6.2]. Median follow-up was 54 months (IQR: 38–76). The reasons for linezolid use were drug-resistant TB in 8 (53%) patients, drug-induced liver injury in 5 (33%) patients and chronic liver disease in 2 (13%) patients. Four children (26%) were on immunosuppressive therapy when TB was diagnosed. Five children (33%) were diagnosed with extrapulmonary TB. The median duration of linezolid treatment was 13 months (IQR: 7.5–17). Nine patients had 13 linezolid-related AEs. Hematologic toxicity was observed in 8 patients (53%) and gastrointestinal intolerance in 3 patients (20%). In 2 patients, linezolid dose was reduced, and in 2 patients, linezolid was discontinued because of AEs. A 2-year-old girl went back to her country of birth and was lost to follow-up. No relapses were observed among the other 14 patients (93%).
Conclusions:
Linezolid may be considered when treating children with drug-resistant TB but also in the cases of patients with chronic liver disease or drug-induced liver injury. However, AEs should be closely monitored. Further studies are needed to determine the optimum dosage and the optimal duration of linezolid treatment in children.
Title: Linezolid-containing Treatment Regimens for Tuberculosis in Children
Description:
Background:
In recent years, there is an increasing interest in the use of linezolid for the treatment of tuberculosis (TB).
Methods:
Patients less than 18 years of age who received linezolid within the Spanish Pediatric TB Network from 2001 to 2016 were retrospectively included.
Treatment characteristics, adverse events (AEs) and outcomes were analyzed.
Results:
Fifteen children were included (53% male) with a median age of 3.
6 years [interquartile range (IQR): 1.
6–6.
2].
Median follow-up was 54 months (IQR: 38–76).
The reasons for linezolid use were drug-resistant TB in 8 (53%) patients, drug-induced liver injury in 5 (33%) patients and chronic liver disease in 2 (13%) patients.
Four children (26%) were on immunosuppressive therapy when TB was diagnosed.
Five children (33%) were diagnosed with extrapulmonary TB.
The median duration of linezolid treatment was 13 months (IQR: 7.
5–17).
Nine patients had 13 linezolid-related AEs.
Hematologic toxicity was observed in 8 patients (53%) and gastrointestinal intolerance in 3 patients (20%).
In 2 patients, linezolid dose was reduced, and in 2 patients, linezolid was discontinued because of AEs.
A 2-year-old girl went back to her country of birth and was lost to follow-up.
No relapses were observed among the other 14 patients (93%).
Conclusions:
Linezolid may be considered when treating children with drug-resistant TB but also in the cases of patients with chronic liver disease or drug-induced liver injury.
However, AEs should be closely monitored.
Further studies are needed to determine the optimum dosage and the optimal duration of linezolid treatment in children.
Related Results
The use of reserve drugs in the chemotherapy of children and adolescents with tuberculosis
The use of reserve drugs in the chemotherapy of children and adolescents with tuberculosis
Introduction. The incidence of tuberculosis in children and adolescents is considered one of the most significant epidemiological indicators, which reflects the overall epidemic si...
Efficacy and Safety of Linezolid in Immunocompromised Patients with Hematological Malignancy
Efficacy and Safety of Linezolid in Immunocompromised Patients with Hematological Malignancy
Abstract
Abstract 4838
BACKGROUND:
The aim of this study was to determine the safety, tolerance and efficacy of l...
DETERMINATION OF SENSITIVITY TO LINEZOLID IN DRUG-RESISTANT TUBERCULOSIS CASES
DETERMINATION OF SENSITIVITY TO LINEZOLID IN DRUG-RESISTANT TUBERCULOSIS CASES
Introduction: Tuberculosis is caused by Mycobacterium tuberculosis and remains a leading infectious cause of mortality globally. Linezolid, an oxazolidinone, has strong in vitro ev...
Immune mechanisms controlling tuberculosis-diabetes co-morbidity
Immune mechanisms controlling tuberculosis-diabetes co-morbidity
<p dir="ltr">Tuberculosis (TB), caused by the bacterium Mycobacterium tuberculosis (M. tuberculosis), remains a leading global health concern, responsible for millions of inf...
Immune mechanisms controlling tuberculosis-diabetes co-morbidity
Immune mechanisms controlling tuberculosis-diabetes co-morbidity
<p dir="ltr">Tuberculosis (TB), caused by the bacterium Mycobacterium tuberculosis (M. tuberculosis), remains a leading global health concern, responsible for millions of inf...
P-1977. Adverse Event Profile of Vancomycin vs. Linezolid in Real-World Reports: A Disproportionality Analysis from the AERS Database
P-1977. Adverse Event Profile of Vancomycin vs. Linezolid in Real-World Reports: A Disproportionality Analysis from the AERS Database
Abstract
Background
Vancomycin and linezolid are critical agents in the treatment of multidrug-resistant gram-positive in...
Impact of HIV and Mycobacterium Tuberculosis Co-Infections on Antioxidant Status in Nigeria
Impact of HIV and Mycobacterium Tuberculosis Co-Infections on Antioxidant Status in Nigeria
Severe Oxidative stress has been reported in Tuberculosis infected individuals as a result of tissue inflammation, poor nutrition and poor immunity and this stress becomes more sev...
Studying cases of extrapulmonary tuberculosis in the National Center for Tuberculosis Control in Damascus
Studying cases of extrapulmonary tuberculosis in the National Center for Tuberculosis Control in Damascus
Abstract
Background :Tuberculosis (TB) is a major public health concern worldwide and is the 13th leading cause of death and the second deadliest infectious disease after C...

